| Species |
Cynomolgus |
| Protein Construction |
IL-17F (Arg31-Gln163)
Accession # G7P4V0-1 |
His |
| N-term |
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Human IL17R alpha, hFc Tag captured on CM5 Chip via Protein A can bind IL-17F, His, Cynomolgus in SPR assay (Biacore T200). Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
16.1 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 23-28 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
The Interleukin 17 (IL-17) family proteins, comprising six members (IL-17A through IL-17F), are secreted, structurally related proteins that share a conserved cystine-knot fold near the C-terminus, but have considerable sequence divergence at the N‑terminus.IL-17F is ligand for IL17RA and IL17RC. The heterodimer formed by IL17A and IL17F is a ligand for the heterodimeric complex formed by IL17RA and IL17RC. Involved in stimulating the production of other cytokines such as IL6, IL8 and CSF2, and in regulation of cartilage matrix turnover. |
| Synonyms |
Cytokine ML-1; IL17F; IL-17F; IL24; IL-24; CANDF6; IL-17F; ML1 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
